Liver Transplant Clinical Trial
Official title:
Effect Of Intraoperative Strict Glycemic Control During Liver Transplantation On Postoperative Morbidity And Mortality
The goal of the proposed study is to evaluate the effectiveness of intraoperative, strict glycemic control to improve survival and infection rates following liver transplantation in a randomized, prospective trial.Primary objective: To determine if strict intraoperative blood glucose control, when compared to standard intraoperative glycemic control, improves 1-year recipient survival and decreases surgical complications, including infections, following liver transplantation.
Approximately 2.1 million patients in the United States acquire infections during medical
care every year. For example, 9%-30% patients who undergo surgery acquire nosocomial
infections, which increase mortality and morbidity over that expected normally expected and
increase the cost of care by several billion dollars. Studies have shown that controlling
high blood glucose levels dramatically improves the recovery of critically ill patients after
surgery, most notably decreasing the risk of infection. The advantage of strict glycemic
control in the critically ill patient is now well accepted, and the Institute for Healthcare
Improvement and Surviving Sepsis Campaign set glycemic control as part of the post-operative
sepsis management bundle.
Few studies have investigated the role of strict glycemic control during surgery itself.
Liver transplantation is a good model for studying glucose control as hyperglycemia almost
always occurs and the incidence of infection is higher than with other surgical procedures.
We performed a retrospective review of 184 consecutive adult liver recipients in which
intra-operative blood glucose levels were measured and treated with insulin. Recipients with
strict glycemic control were compared to those with poor control for differences in donor and
recipient demographics, intra-operative blood glucose concentrations, intra-operative insulin
administered, immunosuppression, post-operative complications, and mortality. Poor glycemic
control was associated with a significantly increased rate of infection during the first 30
days post-operatively (48% vs. 33%, P=0.05) and 1-year mortality was significantly increased
for those recipients with poor intra-operative glucose control (21.9% vs. 8.8%; P = 0.05).
These data along with the post-operative studies, suggest that the post-transplant mortality
rate may potentially be decreased by nearly 50% at 1 year and underscore the need for this to
be confirmed in a prospective trial.
The goal of this study is to prospectively evaluate the outcomes of liver transplant
recipients to either strict glucose control (goal of 80-110 mg/dl) or the current standard of
care (goal of between 180 and 200 mg/dl). The specific aim of this study is to determine if
strict intra-operative blood glucose control, improves 1-year recipient survival and
decreases surgical complications, including infections, following liver transplantation. The
rates of infection at 30 days after surgery and health at one year post- surgery will be
compared. The frequency of other common post-operation complications will also be studied.
The proposed study has the potential to have an impact on the intra-operative management of
all liver transplant recipients.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02798861 -
Controlled Attenuation Parameter (CAP) in Liver Allografts
|
||
Completed |
NCT03527238 -
Optimizing Immunosuppression Drug Dosing Via Phenotypic Precision Medicine
|
Phase 2 | |
Completed |
NCT01696331 -
Text Messaging for Adherence in Adolescent Liver Transplant Recipients
|
N/A | |
Recruiting |
NCT05051605 -
Immune Response to COVID-19 Vaccine in Recipients of Living Donor Liver Transplantation
|
||
Recruiting |
NCT05940857 -
Sponsor-Initiated OCS Liver Perfusion (OLP-II) Registry
|
||
Completed |
NCT01598987 -
Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.
|
Phase 3 | |
Active, not recruiting |
NCT05074160 -
OCS Liver Perfusion (OLP) Post-Approval Registry
|
||
Completed |
NCT05087550 -
Multicenter Study on Organ Acquisition Costs in the Post Re-Allocation Era: Liver Transplantation
|
||
Recruiting |
NCT04836923 -
LIFT Intervention in Liver Transplant Candidates
|
N/A | |
Not yet recruiting |
NCT03666689 -
Outflow Reconstruction in Right Lobe Living Donor Liver Transplantation
|
||
Not yet recruiting |
NCT06088758 -
Normothermic Machine Perfusion of Steatotic Livers for Expansion of Donor Organ Pool
|
N/A | |
Terminated |
NCT01230502 -
Mycophenolic Acid (MPA) Monotherapy in Liver Transplantation
|
N/A | |
Completed |
NCT00171509 -
Efficacy and Safety of Cyclosporine Microemulsion Given Once a Day in Adult Stable Liver Transplant Recipients
|
Phase 4 | |
Not yet recruiting |
NCT06254248 -
Safety of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced Hepatocellular Carcinoma
|
Phase 2 | |
Recruiting |
NCT06075745 -
Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant Candidates
|
Phase 2 | |
Completed |
NCT02057484 -
A 5 Year Follow-up of Patients Who Were Previously Enrolled Into an Advagraf Trial Following a Liver or Kidney Transplant
|
||
Active, not recruiting |
NCT03577431 -
Liver Transplantation With Tregs at MGH
|
Phase 1/Phase 2 | |
Recruiting |
NCT06342557 -
Transitional ePRO Diary Liver
|
||
Not yet recruiting |
NCT04265157 -
Hepato-duodenal Ligament Occlusion and Classic Technique in Liver Transplant
|
||
Recruiting |
NCT02863250 -
Australian and New Zealand Massive Transfusion Registry
|